Management of Blood Pressure in Patients With Diabetes (Q37869806)

24 August 2017

1 reference

title

Management of blood pressure in patients with diabetes (English)

1 reference

24 August 2017

Management of Blood Pressure in Patients With Diabetes (English)

1 reference

30 November 2024

Franz H Messerli

1 reference

24 August 2017

Ehud Grossman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21525967

30 November 2024

language of work or name

1 reference

28 April 2011

1 reference

Journal of Clinical Hypertension

24 August 2017

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

863-875

1 reference

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Diabetic and hypertensive heart disease

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Recommendations for special populations: diabetes mellitus and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The treatment of hypertension in adult patients with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Prevalence of obesity, type II diabetes mellitus, hyperlipidemia, and hypertension in the United States: findings from the GE Centricity Electronic Medical Record database

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Influence of diabetes and type of hypertension on response to antihypertensive treatment.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Cardiac autonomic neuropathy in diabetes: a clinical perspective

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Ambulatory blood pressure variability is increased in diabetic hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Aggressive lipid, hypertension targeting yields no benefit for some with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Left ventricular mass in diabetes-hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of intensive blood-pressure control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of medical therapies on retinopathy progression in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Antihypertensive therapy and new onset diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of valsartan on the incidence of diabetes and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Are calcium antagonists beneficial in diabetic patients with hypertension?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Treatment of hypertension in patients 80 years of age or older

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

New onset diabetes during antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Diuretic induced hyponatraemia in elderly hypertensive women

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Efficacy of Add-On Aldosterone Receptor Blocker in Uncontrolled Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Eplerenone: a review of its use in essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Cardiovascular events during differing hypertension therapies in patients with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Treatment of cardiovascular and renal risk factors in the diabetic hypertensive

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Chinese Trial on Isolated Systolic Hypertension in the Elderly

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2011.77

7 January 2021

Journal of Hypertension

S60

2002

1 reference

Journal of the National Medical Association

30 November 2024

Lea

2002

1 reference

Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial

30 November 2024

1 reference

30 November 2024

Identifiers

DOI

10.1038/AJH.2011.77

1 reference

24 August 2017

1 reference